Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 13,478 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Pancreatic Cancer
Interventions: Chemoradiation (Radiation Therapy), Vorinostat; Radiation · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: AC2993, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 100
States / cities: Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 82 more

Conditions: Bipolar Disorder, Mental Health
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pancreatic Cancer
Interventions: Romidepsin, Gemcitabine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Foot Ulcer, Diabetic
Interventions: No intervention; Other
Lead sponsor: Podimetrics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Propranolol 80 Mg Oral Capsule, Extended Release, Placebo oral capsule; Drug
Lead sponsor: Anu Sharma; Other
Eligibility: 21 Years to 59 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Neoplastic Cells, Circulating, Pancreatic Cancer, Biological Markers
Interventions: No intervention/exposures; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endocrine, Nutritional, Metabolic and Immunity Disorders
Interventions: 50 grams of whole wheat bran cereal, 100 grams of whole wheat bran cereal; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronary Heart Disease, Type 2 Diabetes
Interventions: Once ounce per day of walnuts; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Lifestyle, Home Environment Related Disease, Cardiometabolic Disease, Systemic Inflammatory Response, Health Behavior, Dietary Habits, Physical Inactivity, Self Efficacy, Gut Microbiota, Diabetes Mellitus
Interventions: HomeStyles-China; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 30 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Tele-Monitor DM; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Impaired Fasting Glucose, Prediabetes
Interventions: Re-infusion of biotin labeled cells, Diabetes education/diabetes medication adjustment; Biological · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetic Neuropathy
Interventions: Centella asiatica selected triterpenes (CAST), Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Metastatic Pancreatic Cancer, ERCC1
Interventions: gemcitabine and oxaliplatin; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Type 2 Diabetes, Hyperglycemia
Interventions: sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus; Drug
Lead sponsor: Guillermo Umpierrez, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more

Conditions: Growth Hormone Deficiency
Interventions: MOD-4023, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Vision Disorders, Diabetes
Interventions: AI, Usual Practice; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 22 Years and older
Enrollment: 1,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystic Fibrosis, Diabetes
Interventions: Once-daily insulin detemir; Drug
Lead sponsor: Sydney Children's Hospitals Network; Other
Eligibility: 5 Years to 19 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection; Drug · Device
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: PreDiabetes, Adult Children
Interventions: Metformin, Digital Intervention; Drug · Behavioral
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 44 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Type 2 Diabetes Mellitus, Insomnia, Sleep Disorder, Inflammation
Interventions: Suvorexant, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: NNC0113-2023, Placebo (NNC0113-2023); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Pancreatic Islets of Langerhans Cell Transplant; Procedure
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Gastroparesis
Interventions: Naronapride, Placebo; Drug
Lead sponsor: Dr. Falk Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 23
States / cities: Chula Vista, California • Lomita, California • Clearwater, Florida + 18 more

Search by objective public record fields.

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Reproductive Function and Mood in Women With Bipolar Disorder

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

Approaches to Foot Complication Prevention: A Survey of Diabetes Educators

Propranolol in Treating Hypoglycemia Unawareness

Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma

Wheat Bioactives and Immune Function

Walnut Consumption, Endothelial Function, and Biomarkers

HomeStyles-Adults of Chinese Heritage

Telemedicine Continuous Remote Monitoring of Adults With Uncontrolled Diabetes Mellitus

Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c

Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes

Cystic Fibrosis - Insulin Deficiency, Early Action

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

UVA Islet Cell Transplantation in Patients With Type I Diabetes

Different Doses of Naronapride vs. Placebo in Gastroparesis